Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma
Oncogenic anaplastic lymphoma kinase (ALK) is one of the few druggable targets in neuroblastoma, and therapy resistance to ALK-targeting tyrosine kinase inhibitors (TKIs) comprises an inevitable clinical challenge. Therefore, a better understanding of the oncogenic signaling network rewiring driven by ALK is necessary to improve and guide future therapies. Here, we performed quantitative mass spectrometry–based proteomics on neuroblastoma cells treated with one of three clinically relevant ALK TKIs (crizotinib, LDK378, or lorlatinib) or an experimentally used ALK TKI (TAE684) to unravel aberrant ALK signaling pathway...
Source: Signal Transduction Knowledge Environment - November 20, 2018 Category: Science Authors: Emdal, K. B., Pedersen, A.-K., Bekker-Jensen, D. B., Lundby, A., Claeys, S., De Preter, K., Speleman, F., Francavilla, C., Olsen, J. V. Tags: STKE Research Resources Source Type: news
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways
In this study, we established both phosphoproteomic and gene expression profiles of ALK activity in neuroblastoma cells exposed to first- and third-generation ALK TKIs, to identify the underlying molecular mechanisms and identify relevant biomarkers, signaling networks, and new therapeutic targets. This analysis has unveiled various important leads for novel combinatorial treatment strategies for patients with neuroblastoma and an increased understanding of ALK signaling involved in this disease. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - November 20, 2018 Category: Science Authors: Van den Eynden, J., Umapathy, G., Ashouri, A., Cervantes-Madrid, D., Szydzik, J., Ruuth, K., Koster, J., Larsson, E., Guan, J., Palmer, R. H., Hallberg, B. Tags: STKE Research Resources Source Type: news
Hope for non-toxic treatment for child cancer
Drug combination promising in treating neuroblastoma Related items fromOnMedica One in 10 children in phase I cancer trials respond to drugs Child cancer drug approved for NHS use Children need access to cancer drug ‘goldmine’ Higher heart risk for survivors of childhood cancer Make greater effort to protect children from methadone (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 16, 2018 Category: UK Health Source Type: news
Clinical trial harnesses power of natural killer cells to treat neuroblastoma
(Solving Kids' Cancer) Researchers use a humanized monoclonal antibody known as hu14.18-IL2, which specifically targets neuroblastoma tumor cells and binds to them. The humanized monoclonal antibody may be more effective at activating the NK cells for killing the cancer cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2018 Category: International Medicine & Public Health Source Type: news
Drug combination makes cancer disappear in mice with neuroblastoma
(ECCO-the European CanCer Organisation) Researchers investigating new treatments for neuroblastoma -- one of the most common childhood cancers -- have found that a combination of two drugs made tumors disappear in mice, making it more effective than any other drugs tested in these animals. The research is presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 14, 2018 Category: Cancer & Oncology Source Type: news
A nine-year-old boy who bravely endured years of gruelling treatment is now free of cancer
Henry Hallam, from Plymouth, was diagnosed with neuroblastoma when he was three years old. It affects 100 UK children each year and has one of the lowest survival rates - but he beat it. (Source: the Mail online | Health)
Source: the Mail online | Health - October 31, 2018 Category: Consumer Health News Source Type: news
Translational research on recurrent metastatic neuroblastoma at Children's Hospital Los Angeles
(Children's Hospital Los Angeles) A team of investigators at CHLA designed basic research studies to look at the effects of dinutuximab and activated natural killer cells on recurrent disease and overall survival in neuroblastoma. This research provided proof-of-concept for an upcoming clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 3, 2018 Category: Cancer & Oncology Source Type: news
Could Zika Virus Potentially Treat Neuroblastoma?
Researchers report that the same driving force that makes Zika so detrimental to unborn babies gives it promise as a cancer treatment. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
Girl battling a rare cancer for third time meets Little Mix
Rosie Veronica Mitchell, Port Glasgow, Inverclyde, is battling neuroblastoma - a rare childhood cancer that usually starts in the abdomen. (Source: the Mail online | Health)
Source: the Mail online | Health - August 8, 2018 Category: Consumer Health News Source Type: news
Urgent appeal is underway to send a six-year-old girl abroad for cancer treatment
Rosie Veronica Mitchell, Port Glasgow, Inverclyde, is battling neuroblastoma - a rare childhood cancer that usually starts in the abdomen. (Source: the Mail online | Health)
Source: the Mail online | Health - August 8, 2018 Category: Consumer Health News Source Type: news
Solid tumors targeted in new CAR T-Cell immunotherapy trial
(Seattle Children's) Seattle Children's has opened a chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory non-central nervous system EGFR-expressing solid tumors. In the phase 1 trial, STRIvE-01, cancer-fighting CAR T cells will target the EGFR protein expressed in many childhood sarcoma, kidney and neuroblastoma tumors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 7, 2018 Category: International Medicine & Public Health Source Type: news
Beat Childhood Cancer Consortium expands into Canada
(Spectrum Health) Helen DeVos Children's Hospital's consortium, known as Beat Childhood Cancer (BCC), announced today that through a partnership with The C17 Council, the organization's first Canadian clinical trial site, Centre Hospitalier Universitaire de Sainte-Justine, Montreal, Quebec, Canada, has been approved to begin recruiting patients for a pivotal clinical trial investigating the potential of a repurposed drug to prevent relapse in patients diagnosed with high-risk neuroblastoma who are currently in remission. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 6, 2018 Category: International Medicine & Public Health Source Type: news
Zika viruses show potential as treatment for high-risk childhood cancer
(Nemours) Zika virus may hold potential as a cancer treatment for neuroblastoma, a rare-but-deadly childhood cancer, according to early findings from basic research published today in PLOS ONE. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 25, 2018 Category: Cancer & Oncology Source Type: news
Cancer drug for children recommended after becoming cost effective for NHS patients
Seriously ill children battling high-risk neuroblastoma, a rare type of cancer that mainly affects children and young people, are to be offered a drug which has potential to extend their lives. (Source: NHS Networks)
Source: NHS Networks - July 12, 2018 Category: UK Health Source Type: news
Child cancer drug approved for NHS use
60% of children with high-risk neuroblastoma can be treated with dinutuximab beta Related items fromOnMedica One in 10 children in phase I cancer trials respond to drugs Children need access to cancer drug ‘goldmine’ NICE rejects adjuvant use of breast cancer drug New breast cancer drug ‘unaffordable’ for NHS Drug could double head and neck cancer survival (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 12, 2018 Category: UK Health Source Type: news
